Following on from last year's successful NIHR BRC Showcase, MedCity, the NIHR, and the Cell and Gene Therapy Catapult are hosting a second event focused on Cell and Gene Therapy.
Formed through partnerships between leading NHS organisations and universities, National Institute for Health Research Biomedical Research Centres (BRCs) conduct translational research to transform scientific breakthroughs into life-saving treatments for patients.
Join us at Kings Place, London on Thursday 15 March to hear from and network with renowned BRCs from across Cambridge, London and Oxford, find out about their successful projects and better understand the opportunities available to work collaboratively with the BRCs.
9.00 Arrival, Registration and Coffee
9.15 – 9:30 Introduction and Welcome (Professor Simon Howell, MedCity Catalyst Fund Grant Holder and Director of Academic Estates Strategy for Health Campuses, King’s College London)
9:30 – 9:50 Overview of the NIHR Biomedical Research Centres (TBC)
9:50 – 10:10 The role of the Cell and Gene Therapy Catapult in accelerating commercialisation of research (Matthew Durdy, Chief Business Officer, Cell and Gene Therapy Catapult)
10:15 – 11:15 Panel Discussion: Perspectives in transitioning from the development of cell and gene therapies to commercialisation
- Chair: Sarah Haywood, CEO, MedCity
- Professor Emma Morris, UCLPartners
- Bobby Gaspar, Chief Scientific Officer, Orchard Therapeutics
- Professor Ludovic Vallier, Wellcome Sanger Institute
- Dr Jim Faulkner, Senior Vice President, Autolus
- Matthew Durdy, Chief Business Officer, Cell and Gene Therapy Catapult
11.45 – 15.00 Biomedical Research Centre Exhibition and Lunch
Take this opportunity to network with the BRCs and find out about their capabilities along the therapy development pathway; including cell and gene therapy portfolio, clinical delivery and commercialisation. It includes:
- NIHR Cambridge BRC
- NIHR Great Ormond Street Hospital BRC
- NIHR Guy’s and St Thomas’ BRC
- NIHR Imperial BRC
- NIHR Moorfields BRC
- NIHR Royal Marsden BRC
- NIHR University College London Hospitals BRC
- NIHR Oxford BRC
- Cell and Gene Therapy Catapult
13.00 – 16.00 Masterclasses, 1:1s and networking
- Accelerating translation of the academic pipeline
The UCL Translational Research Office and UCL Business will outline the ways in which they support translation and commercialisation of cell and gene therapy including successful case studies.
- Oncolytic viruses as a new gene therapy
This masterclass by Professor Alan Melcher, Professor of Translational Immunology and Honorary Consultant Oncologist at The Royal Marsden Hospital, will describe the science underlying the potential of oncolytic viruses as an exciting novel form of gene immunotherapy, and show how these agents are starting to impact as deliverable new treatments within the clinical landscape’.
- From Idea to Adoption – the NIHR Innovation Pathway
The NIHR’s Clare Woods, Business Development Manager, and Ginette Hoare, Industry Operations Manager, will explore the many ways that the NIHR is supporting industry to deliver early phase translational research in the NHS, through research funding, access to expertise and study support.
- The importance of early planning for ATMP reimbursement
Given the high cost of cell and gene therapies and the commercial risks they face, certain health-economic activities should be undertaken prior to starting clinical development. Panos Kefalas, Head of Health Economics and Market Access at the Cell and Gene Therapy Catapult, will explain why it is important to conduct these activities, what they entail and the benefits they deliver in securing commercial viability.
Register to attend this event to find out more about the BRCs and how to collaborate and benefit from their clinical and scientific expertise.
If you have any enquiries, please contact Nivashinee Krishnakumar, Business Support Officer at MedCity, on email@example.com or +44 (0)20 3179 8100.